mycophenolate mofetil
mycophenolate mofetil: 28 clinical trials tracked.
mycophenolate mofetil evidence translation
What we can confirm
28 tracked trials
What it means
What to watch
Prepared research question
What is verified about mycophenolate mofetil, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 7 study sponsors
Related indications
Clinical Trials (28)showing 10 most recent
Efficacy and Safety of Mycophenolate Mofetil in Patients With Refractory IgA Nephropathy in Bangladesh: A Phase II Randomized Controlled Trial
Primary endpoint: Proportion of participants achieving complete remission
Pilot Study of Emapalumab With Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis for Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation
Primary endpoint: Incidence of grade 3 or higher adverse events (AEs)
Mycophenolate Mofetil to Overcome Glioblastoma Resistance to Radiotherapy and Temozolomide
Primary endpoint: Progression free survival (PFS) (phase II)
A Phase I Study to Evaluate the Safety of Ruxolitinib in Combination With Azacitidine Maintenance in Patients Undergoing Reduced Intensity Allogeneic Transplant for Acute Myeloid Leukemia (AML)
Primary endpoint: Incidence of dose limiting toxicities (DLTs)
A Seamless Phase 2/3 Randomized, Open-label Study to Investigate Efficacy and Safety of Frexalimab Versus Tacrolimus in Adult Kidney Transplant Recipients
Primary endpoint: Composite efficacy failure rate (BPAR, graft loss, and death) by 1 year post kidney transplantation
Randomized Pilot Study of Ruxolitinib for Switch-Maintenance Prophylaxis of Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation After Intermediate-Dose Post-Transplant Cyclophosphamide (Rux Switch-Maintenance in Intermediate PTCY: RuSMa-PTCY) in Comparison to Full-Dose PTCY
Primary endpoint: assess cGVHD-free survival
A Phase 2 Study of Fludarabine and Intermediate-dose Total Body Irradiation (800 cGy) Followed by Post-transplant Cyclophosphamide in Patients Aged 18-65 Undergoing Allogeneic Stem Cell Transplant for Hematologic Malignancies
Primary endpoint: Overall survival (OS) at 1-year following treatment with fludarabine plus intermediate-dose total body irradiation (TBI 800 cGy) with post-transplant cyclophosphamide (PTCy)
Ruxolitinib Based GVHD Prophylaxis Regimen for Older Adults Receiving Non-ATG Containing Non-Myeloablative Hematopoietic Cell Transplantation for Acquired Aplastic Anemia
Primary endpoint: Incidence of grades II-IV acute graft-versus-host disease (GVHD)
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
Primary endpoint: GVHD-free survival (GFS)
Efficacy & Safety of Pharmacokinetically-Driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis- A Double-Blind Placebo Controlled Clinical Trial
Primary endpoint: To compare the efficacy of MMFPK therapy to the efficacy of MMFBSA therapy